DOCSLIB.ORG

Batten Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Batten Disease Investigating Batten disease JONA PROFESSOR Professor Jonathan Mink discusses a rare childhood neurological disorder – Batten disease – delving into its peculiarities, the difficulties associated with studying rare diseases, methods of clinical evaluation and potential future treatment options THA Batten disease explained N MINK Could you discuss some of the ongoing Neuronal ceroid lipofuscinoses clinical trials evaluating disease-modifying (NCLs) are a group of lysosomal storage therapies? diseases characterised by the accumulation of a lipopigment in neurons. There are at least Disease-modifying therapies currently 12 different forms of NCL, the most prevalent of undergoing investigation in human trials which is the juvenile form (JNCL, or Batten disease), include gene therapy, enzyme-replacement due to mutations in the CLN3 gene. therapy and immunomodulation. For the forms of Batten disease that involve Batten disease is characterised by rapidly soluble enzymes (eg. CLN1 and CLN2 progressive blindness beginning between four and diseases), gene and enzyme-replacement seven years, followed by progressive dementia, therapy are promising strategies. In juvenile epilepsy and premature death (usually in neuronal ceroid lipofuscinoses (JNCL, or the third decade). Incidence is estimated CLN3 disease), the protein is membrane-bound to be about two per 100,000 live and poorly understood, so therapy directed at births in the US. replacing the mutant protein is less feasible. However, work by David Pearce, PhD of the Sanford Children’s Health Research Center You employ standardised measures to has shown that children and mouse models disease, another rare childhood neurological conduct your evaluations. How do you with CLN3 disease have antibody-mediated disease. Our systematic approach to accommodate the unique phenotype of autoimmunity. In mice, suppression of the quantifying disease progression puts us in a Batten disease? immune response is protective. We are currently strong position to test treatment efficacy. performing a phase II clinical trial of the Wherever possible we aim to use standardised immunosuppressant mycophenolate mofetil in It is becoming increasingly apparent measures that do not require adaptation; children with CLN3 disease. that many neurodegenerative diseases for example, assessment tools that do not have an inflammatory component. If necessitate examination of visual stimuli. Due to the rarity of the condition, the Batten immunomodulation can slow CLN3 disease However, when adaptations are necessary we disease research community is relatively progression, it could provide important insights carefully document and maintain them. small. As such, do you find collaboration is an into the treatment of other lysosomal storage integral part of your work? disorders that affect the nervous system. We developed the Unified Batten Disease Rating Scale (UBDRS) and used iterative Collaboration is of critical importance in What are the main hurdles to developing methods to assure reliability. Even after a rare disease research generally and in Batten effective treatments? decade of evaluations, we continue to learn disease research specifically. Collaboration is how to further refine our assessments to necessary to develop consensus about how to At this time, potential treatments are more improve the sensitivity of the methods, prioritise treatment trials; develop agreement likely to slow or halt disease progression especially during the latter stages of disease. on meaningful endpoints for clinical trials; than reverse it. In addition to the difficulty of and enrol sufficient numbers of subjects in identifying and testing such a treatment, this The Pediatric Quality of Life Family Impact clinical trials. poses the challenge of identifying potential Module assesses the health-related candidates as early in the disease course as quality of life of parents and family Batten disease shares challenges with other possible, in order to have the best outcome – in relation to the child’s health. What lysosomal storage disorders. To what extent requiring early diagnosis. conclusions were you able to draw from will your research advance knowledge on your research? these rare diseases? Can you describe some of the greatest achievements your team has made to date? These results show the considerable impact Our approach to studying the natural of the disease upon the wellbeing of the history of JNCL has significant potential to Our greatest achievements have been family. Batten disease does not just affect a inform research on other rare childhood conducting the largest longitudinal study child, but an entire family system. The results neurodegenerative diseases. We have of the natural history of any form of NCL, also suggest that the care we provide must developed a disease-specific rating scale that developing the methodology and infrastructure take into consideration the needs of the can be modified for other diseases. In fact, for clinical trials in Batten disease and initiating family as a whole. it has already been employed for Wolfram the first controlled clinical trial in JNCL. WWW.RESEARCHMEDIA.EU 85 PROFESSOR JONATHAN MINK Rare disease clinical trials The University of Rochester Medical Center, a Batten disease Center of Excellence, is conducting the first controlled clinical trial for the juvenile form of the disease. It is hoped their work characterising the course of the condition will improve diagnosis and treatment, benefiting child patients and their families alike discovered an immune component SCALE OF DISEASE to JNCL, a monumental finding for a disease about which so little is The Unified Batten Disease Rating Scale understood. URBC researchers take a (UBDRS) was developed by the URBC to provide quantitative approach to the study of a consistent and disease-specific method of JNCL progression, which will inform evaluating children with JNCL. It is a multi- neurobiological investigations and component system, comprising a physical clinical trials. exam, medical history review and questioning about symptoms. The UBDRS is used both as There are many challenges associated part of clinical evaluation and as a research tool. with studying Batten disease: like all rare diseases, the number of affected The Scale is modelled after scales in similar people willing to enter clinical trials adult disorders and has four subscales: physical is small; those who are willing need impairment, seizures, behaviour and functional From left to right: Heather Adams, Sara Defendorf, Lisa de Blieck, Jonathan Mink, to be diagnosed early, which can capability. Since 2002, 120 children have Frederick Marshall, Amy Vierhile, Paul Rothberg, Alyssa Thatcher, Erika Augustine. be a difficult proposition; and by been evaluated using the UBDRS, and many its rare nature, there are relatively return each year. Repeat evaluations allow the few people working on the disease. team to consistently track disease progression ALTHOUGH RELATIVELY RARE, neuronal Overcoming these many and varied obstacles over time. Ultimately, the system enables ceroid lipofuscinoses (NCLs) represent the requires collaboration, training a new generation the identification of symptoms which lead to most common neurodegenerative disorders of of rare disease researchers and leveraging existing disability and factors which are associated with childhood. The University of Rochester Medical resources. However, great advances in genetics fewer symptoms. Center (URMC) studies Batten disease, the most alongside growing knowledge of JNCL’s clinical common form of NCL. features suggest meaningful therapeutics could The URBC investigators have recently shown be available in the not too distant future. that the physical impairment subscale can NCLs are a broad class of diseases. Although be used remotely by a trained non-physician. they share some symptoms and pathology, there Telemedicine has real potential to be a valuable RESEARCH CATEGORIES are great differences in terms of age of onset, tool in NCL research and clinical assessment, a biochemistry and genetics; there are at least 20 The overarching aims of studies at URBC are to real benefit given the geographically scattered genes associated with Batten disease alone. The advance knowledge of the clinical manifestations nature of patients. most prevalent form of Batten disease is juvenile of Batten disease and to develop improved NCL (JNCL), which is linked to mutations in treatments. Under this umbrella, research CLINICAL TRIAL CLN3. CLN3 encodes Battenin, a ubiquitously is divided into four basic categories: natural expressed membrane protein localised to the history; neurobehavioural and neurocognitive The past 20 years of JNCL research has seen a lysosomal membrane. Although its function is features; determinants of JNCL severity; and shift from the bench to the bedside. Forming unknown, modelling studies suggest it may play experimental therapeutics. part of this transition, URBC has developed a a role in substrate trafficking along the lysosomal clinical research infrastructure, research cohort pathway in cells. Neurobehavioural assessment of patients with and disease-specific clinical outcome measure. JNCL is particularly demanding. Dementia and This pathway is hugely important to cellular vision loss in JNCL place limits on assessment, Designing and carrying out meaningful clinical transport and metabolism; lysosomes essentially as many intelligence tests evaluate both verbal trials is a major emphasis of URBC research.
Load more

Recommended publications
  • Soonerstart Automatic Qualifying Syndromes and Conditions 001
    SoonerStart Automatic Qualifying Syndromes and Conditions 001 Abetalipoproteinemia 272.5 002 Acanthocytosis (see Abetalipoproteinemia) 272.5 003 Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) 760.79 004 Acidemia, 2-Oxoglutaric 276.2 005 Acidemia, Glutaric I 277.8 006 Acidemia, Isovaleric 277.8 007 Acidemia, Methylmalonic 277.8 008 Acidemia, Propionic 277.8 009 Aciduria, 3-Methylglutaconic Type II 277.8 010 Aciduria, Argininosuccinic 270.6 011 Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) 759.89 012 Acrocephalopolysyndactyly Type II 759.89 013 Acrocephalosyndactyly Type I 755.55 014 Acrodysostosis 759.89 015 Acrofacial Dysostosis, Nager Type 756.0 016 Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) 759.89 017 Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) 759.89 018 Aglossia Congenita (see Hypoglossia-Hypodactylia) 759.89 019 Albinism, Ocular (includes Autosomal Recessive Type) 759.89 020 Albinism, Oculocutaneous, Brown Type (Type IV) 759.89 021 Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) 759.89 022 Albinism, Oculocutaneous, Tyrosinase Positive (Type II) 759.89 023 Albinism, Oculocutaneous, Yellow Mutant (Type IB) 759.89 024 Albinism-Black Locks-Deafness 759.89 025 Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) 759.89 026 Alexander Disease 759.89 027 Alopecia - Mental Retardation 759.89 028 Alpers Disease 759.89 029 Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) 271.0 030 Alpha-L-Fucosidase Deficiency (see Fucosidosis)
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptJ Registry Author Manuscript Manag. Author Author Manuscript manuscript; available in PMC 2015 May 11. Published in final edited form as: J Registry Manag. 2014 ; 41(4): 182–189. Exclusion of Progressive Brain Disorders of Childhood for a Cerebral Palsy Monitoring System: A Public Health Perspective Richard S. Olney, MD, MPHa, Nancy S. Doernberga, and Marshalyn Yeargin-Allsopp, MDa aNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC) Abstract Background—Cerebral palsy (CP) is defined by its nonprogressive features. Therefore, a standard definition and list of progressive disorders to exclude would be useful for CP monitoring and epidemiologic studies. Methods—We reviewed the literature on this topic to 1) develop selection criteria for progressive brain disorders of childhood for public health surveillance purposes, 2) identify categories of disorders likely to include individual conditions that are progressive, and 3) ascertain information about the relative frequency and natural history of candidate disorders. Results—Based on 19 criteria that we developed, we ascertained a total of 104 progressive brain disorders of childhood, almost all of which were Mendelian disorders. Discussion—Our list is meant for CP surveillance programs and does not represent a complete catalog of progressive genetic conditions, nor is the list meant to comprehensively characterize disorders that might be mistaken for cerebral
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • Dysregulation of Autophagy As a Common Mechanism in Lysosomal
    University of Birmingham Dysregulation of autophagy as a common mechanism in lysosomal storage diseases Seranova, Elena; Connolly, Kyle J; Zatyka, Malgorzata; Rosenstock, Tatiana R; Barrett, Timothy; Tuxworth, Richard I; Sarkar, Sovan DOI: 10.1042/EBC20170055 10.1042/EBC20170055 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Seranova, E, Connolly, KJ, Zatyka, M, Rosenstock, TR, Barrett, T, Tuxworth, RI & Sarkar, S 2017, 'Dysregulation of autophagy as a common mechanism in lysosomal storage diseases', Essays in Biochemistry, vol. 61, no. 6, pp. 733-749. https://doi.org/10.1042/EBC20170055, https://doi.org/10.1042/EBC20170055 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 08/01/2018 General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • Batten Disease
    Batten Disease Batten disease (Neuronal Ceroid Lipofuscinoses) is an inherited disorder of the nervous system that usually manifests itself in childhood. Batten disease is named after the British paediatrician who first described it in 1903. It is one of a group of disorders called neuronal ceroid lipofuscinoses (or NCLs). Although Batten disease is the juvenile form of NCL, most doctors use the same term to describe all forms of NCL. Early symptoms of Batten disease (or NCL) usually appear in childhood when parents or doctors may notice a child begin to develop vision problems or seizures. In some cases the early signs are subtle, taking the form of personality and behaviour changes, slow learning, clumsiness or stumbling. Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight and motor skills. Children become totally disabled and eventually die. Batten disease is not contagious nor, at this time, preventable. To date it has always been fatal. Click here to return to the top of the page What are the forms of NCL? There are four main types of NCL, including a very rare form that affects adults. The symptoms of all types are similar but they become apparent at different ages and progress at different rates. Infantile NCL: (Santavuori-Haltia type) begins between about 6 months and 2 years of age and progresses rapidly. Affected children fail to thrive and have abnormally small heads (microcephaly). Also typical are short, sharp muscle contractions called myoclonic jerks. Patients usually die before age 5, although some have survived a few years longer.
    [Show full text]
  • Metachromatic Leukodystrophy Improved Diagnosis and Prognosis
    rJhlly /_ o I ME TACTIROMATIC LEUKODYS TR IMPROVED DIAGNOSIS ANI) PROGI{OSIS by Mohd Adi Firdaus TAN B.Biomedical Sc. (Hons) Department of Paediatrics The University of Adelaide Adelaide, South Australia This thesis is submitted for the degree of Doctor of Philosophy Date submitted: z8 March 2o,o,6 THESIS SUMMARY mole prevalent lysosomal storage Metachromatic leukodystrophy (MLD) is one of the births in Australia' The major cause of disorders with a reported incidence of I in 92,000 (ASA); this lysosomal enzyme, together this disease is the deficiency of arylsulphatase A of sulphatide' The with an activator protein, saposin B, is needed for the catabolism nervous system results in progressive subsequent accumulation of sulphatides in the central neurorogical function with a fatal outcome demyerination that reads to severe impairment of juvenile patients. for the more sevefely affected infantile and - l);. .1 MLD patients for more thanz' years' Bone marrow transprantation has been carried out in diffrcurt and remains a challenge However, successfur treatment of this disorder is often onset of neurological symptoms' At because patients are usually diagnosed after the in peripheral blood leucocltes present, MLD is diagnosed by measurement of ASA activity diagnosis is usually only obtained after and cultured skin fibroblasts. However, a definitive tests. The need for auxiliary tests is extensive testing with an arcay ofauxiliary laboratory (ASA-PD) mutation or ASA-PD/MLD' due to the presence of the ASA pseudo-deficiency low ASA enzyme activity' These which leads to clinically normal individuals who have conventional enzyme analysis; patients cannot be distinguished from MLD patients by MLD since saposin B deficiency is furthermore, normal enzyme activity cannot rule out also known to cause the disorder' and a simple skin fibroblast In this study, immune-based ASA activity and protein assays, a sulphatide quantification assay sulphatide-loading protocol, were developed.
    [Show full text]
  • Inborn Errors of Metabolism As a Cause of Neurological Disease in Adults: an Approach to Investigation
    J Neurol Neurosurg Psychiatry 2000;69:5–12 5 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.1.5 on 1 July 2000. Downloaded from REVIEW Inborn errors of metabolism as a cause of neurological disease in adults: an approach to investigation R G F Gray, M A Preece, S H Green, W Whitehouse, J Winer, A Green In 1927 Archibald Garrod presented the Hux- LYSOSOMAL STORAGE DISEASES ley Lecture at Charing Cross Hospital1 Out of The lysosome is an intracellular organelle this lecture emerged the concept of an “inborn involved in the degradation of various complex error of metabolism” whereby an inherited lipids, glycoproteins, and mucopolysaccha- defect may lead to the accumulation in cells or rides. Defects in specific enzymes lead to the body fluids of a metabolite which in itself may accumulation of complex catabolic intermedi- predispose to disease. The disorders cited as ates. Although the process occurs in utero the examples were all adult onset disorders. age of onset of clinical symptoms can vary sub- Today there are over 200 known inborn stantially. Alleles are known which are associ- errors of metabolism; however, the vast major- ated with a milder, later onset phenotype. This ity of cases reported are of childhood onset may be related to the presence of significant (<16 years of age). In part this may reflect the residual functional enzyme activity resulting in fact that the paediatric forms of the disease are a lower rate of accumulation of the intermedi- more severe and hence more easily recognis- ate metabolite. The clinical symptoms of the able.
    [Show full text]
  • Early Differential Diagnosis of Infantile Neuronal Ceroid Lipofuscinosis, Rett Syndrome, and Krabbe Disease by CT and MR
    Early Differential Diagnosis of Infantile Neuronal Ceroid Lipofuscinosis, Rett Syndrome, and Krabbe Disease by CT and MR Sanna-Leena Vanhanen, Raili Raininko, and Pirkko Santavuori PURPOSE: To compare early radiologic findings in three clinically similar progressive encepha­ lopathies of childhood. METHODS: Brain CT and/ or MR studies were done in 57 children 3 to 36 months of age: 16 with infantile neuronal ceroid lipofuscinosis, 5 with Rett syndrome, 6 with Krabbe disease, and 30 control subjects with normal neurologic status. In addition, previous descriptions in the literature were collected. RESULTS: No significant changes were seen in Rett syndrome. Early atrophy was found in infantile neuronal ceroid lipofu scinosis and in Krabbe disease, being more severe in the latter. The thalami were hyperdense in 4 of 13 patients with infantile neuronal ceroid lipofuscinosis and in 1 of 4 patients with Krabbe disease (in the literature in 12 of 30 examinations). Cerebral calcifications and density abnormalities in the cerebral and cerebellar white matter were seen in Krabbe disease only . On MR, the white matter changes in the two diseases were differently located. In every patient with infantile neuronal ceroid lipofu scinosis, decreased T2 signal was seen in the thalami and periventricular high-signal rims after the age of 13 months. Hypointensity of the thalami and basal ganglia was seen in both diseases , but Krabbe disease showed more variations. Abnormalities of cerebellar intensity were found in Krabbe disease only. CONCLUSIONS: CT and MR are of value in the differential diagnosi s of these three diseases. MR especially facilitates the early diagnosis of infantile neuronal ceroid lipofuscinosi s.
    [Show full text]
  • Leukemia to Leukodystrophy: Curative Role of Umbilical Cord Blood Transplantation
    Leukemia to Leukodystrophy: Curative Role of Umbilical Cord Blood Transplantation Vinod K. Prasad, MD, MRCP (London) Pediatric Marrow and Stem Cell Transplantation, Duke University Hematopoietic Stem Cell Transplantation Peripheral Blood Umbilical Cord Bone Marrow Stem Cell Blood All Rights Reserved, Duke Medicine 2007 Hematopoietic Stem Cell Transplantation Fundamental Concepts Elimination of Hematopoietic elements in bone marrow and other organs (Myeloablation) then Marrow Reconstitution Hematopoietic Stem Cell Transplant versus Solid Organ Transplant All Rights Reserved, Duke Medicine 2007 • Mendelian Inheritance - 25% chance of matching • Overall chance in the sibship = 1- (0.75)n n = number of siblings • USA – 25-30% chance of finding a matched sibling • Higher chances in inbred and consanguineous marriage All Rights Reserved, Duke Medicine 2007 Hematopoietic Stem Cell Transplant • Allogeneic • Matched • Autologous • Mismatched • Syngeneic • Haplo donor • Xenogeneic • Myeloablative • PBSCT • Non-Myeloablative • Cord Blood Transplant •BMT • Related Donor • T-Cell depleted • Unrelated Donor All Rights Reserved, Duke Medicine 2007 Unrelated Donor Transplants by NMDP (Be-The-Match Registry) Total Numbers Patients < 18 years old All Rights Reserved, Duke Medicine 2007 UCB-T for Malignant Diseases • Acute Leukemia – Acute Lymphoblastic Leukemia (ALL) – Acute Myelogenous Leukemia (AML) – Secondary AML – Acute Undifferentiated Leukemia and Biphenotypic Leukemia • Chronic Leukemia – Chronic Myelogenous Leukemia (CML) – Juvenile CML (JCML)
    [Show full text]
  • Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
    551 38 Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses Marie T. Vanier, Catherine Caillaud, Thierry Levade 38.1 Disorders of Sphingolipid Synthesis – 553 38.2 Sphingolipidoses – 556 38.3 Niemann-Pick Disease Type C – 566 38.4 Neuronal Ceroid Lipofuscinoses – 568 References – 571 J.-M. Saudubray et al. (Eds.), Inborn Metabolic Diseases, DOI 10.1007/978-3-662-49771-5_ 38 , © Springer-Verlag Berlin Heidelberg 2016 552 Chapter 38 · Disor ders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses O C 22:0 (Fatty acid) Ganglio- series a series b HN OH Sphingosine (Sphingoid base) OH βββ β βββ β Typical Ceramide (Cer) -Cer -Cer GD1a GT1b Glc ββββ βββ β Gal -Cer -Cer Globo-series GalNAc GM1a GD1b Neu5Ac βαββ -Cer Gb4 ββ β ββ β -Cer -Cer αβ β -Cer GM2 GD2 Sphingomyelin Pcholine-Cer Gb3 B4GALNT1 [SPG46] [SPG26] β β β ββ ββ CERS1-6 GBA2 -Cer -Cer ST3GAL5 -Cer -Cer So1P So Cer GM3 GD3 GlcCer - LacCer UDP-Glc UDP Gal CMP -Neu5Ac - UDP Gal PAPS Glycosphingolipids GalCer Sulfatide ββ Dihydro -Cer -Cer SO 4 Golgi Ceramide apparatus 2-OH- 2-OH-FA Acyl-CoA FA2H CERS1-6 [SPG35] CYP4F22 ω-OH- ω-OH- FA Acyl-CoA ULCFA ULCFA-CoA ULCFA GM1, GM2, GM3: monosialo- Sphinganine gangliosides Endoplasmic GD3, GD2, GD1a, GD1b: disialo-gangliosides reticulum KetoSphinganine GT1b: trisialoganglioside SPTLC1/2 [HSAN1] N-acetyl-neuraminic acid: sialic acid found in normal human cells Palmitoyl-CoA Deoxy-sphinganine + Serine +Ala or Gly Deoxymethylsphinganine 38 . Fig. 38.1 Schematic representation of the structure of the main sphingolipids , and their biosynthetic pathways.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,604,011 B2 Melon (45) Date of Patent: Dec
    USOO8604011 B2 (12) United States Patent (10) Patent No.: US 8,604,011 B2 MelOn (45) Date of Patent: Dec. 10, 2013 (54) THERAPY FORTREATMENT OF CHRONIC OTHER PUBLICATIONS DEGENERATIVE BRAIN DISEASES AND NERVOUS SYSTEM INJURY Frolov (The JBC, 2003, 278, 28, p. 25517-25525).* NINDS, NIH document (http://www.ninds.nih.gov/disorders/ (75) Inventor: Synthia Mellon, San Francisco, CA niemann/niemann.htm), 2010, p. 1-2.* (US) Timby, Gynecological Endocrinology, 2010, p. 1-7.* Mellon (Brain Research Reviews, 2008, 410-420).* 73) Assignee:9. The Regentsg of the UniversitVy of Burns et al. (Nature Medicine, vol. 10, 7, Jul. 2004).* California, Oakland, CA (US) Bramlett, K. S. et al., “A Natural Product Ligand of the Oxysterol Receptor, Liver X Receptor'. The Journal of Pharmacology and *) Notice: Subject to anyy disclaimer, the term of this Experimental Therapeutics, vol. 307, pp. 291-296 (2003). patent is extended or adjusted under 35 Collins, Jon L., “Therapeutic opportunities for liver X receptor U.S.C. 154(b) by 781 days. modulators'. Current Opinion in Drug Discovery & Development, vol. 7, No. 5, pp. 692-702 (2004). Griffin, Lisa D. et al., “Niemann-Pick type C disease involves dis (21) Appl. No.: 11/576,125 rupted neurosteroidogenesis and responds to allopregnanolone'. (22) PCT Filed: Sep. 27, 2005 Nature Medicine, vol. 10, No. 7, pp. 704-711 (2004). di Michelle, F. et al., “Decreased plasma and cerebrospinal fluid (86). PCT No.: PCT/US2OOS/O34746 content of neuroactive steroids in Parkinson's disease'. Neurol. Sci. vol. 24, pp. 172-173 (2003). S371 (c)(1), Reddy, D.
    [Show full text]
  • Batten Disease Support and Research Association (BDSRA)
    Batten Disease Neuronal Ceroid Lipofuscinosis An Easy to Understand Guide A Publication of the Batten Disease Support and Research Association Acknowledgment We wish to extend our sincere thanks to The American Legion Child Welfare Foundation, Inc. the organization whose generous grant made publication of this book possible. Notice to the Reader: All material in this book is provided for information purposes only. Although Batten Disease Support and Research Association (BDSRA) has made every reasonable effort to assure the accuracy of the information contained in this book, BDSRA is not engaged in rendering medical or other professional services and advice. BDSRA does not guarantee or warrant that the information in the book is complete, correct, current, or applicable to every situation. BDSRA disclaims all warranties, express or implied, concerning this book and the information contained herein. If medical or other expert assistance is required, the services of a competent professional should be obtained. Introduction Batten Disease is the common name for a group of illnesses whose medical term/name is Neuronal Ceroid Lipofuscinosis (NCL). When the NCLs are discussed they are often referred to as forms of Batten Disease. In fact, they all have the same basic cause, same progression and same outcome. However, they are differentiated by age of onset, rapidity of progression and are the result of defects of different genes. Throughout this document whenever a word is shown in BOLD, it can be found in the glossary and the terms Batten Disease and NCL will be used interchangeably. This document is meant to be a source of information in layman's language and is not intended to be a definitive treatise on Batten Disease.
    [Show full text]